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Abstract
Introduction: Hyperbilirubinemia is a common side effect of the antiretroviral agent atazanavir
but is generally reversible upon discontinuation of treatment. We used therapeutic drug
monitoring to investigate the occurrence of hyperbilirubinemia in a 49-year-old Hispanic man
infected with HIV, following an overdose of ritonavir in ritonavir-boosted atazanavir therapy.
Case presentation: A 49-year-old Hispanic man with HIV who had received several highly active
antiretroviral therapy regimens over a number of years including atazanavir-containing regimens,
was diagnosed with hyperbilirubinemia. An inappropriate doubling of ritonavir boosting resulted in
a high atazanavir Ctrough and an initial rise in bilirubin plasma levels. Bilirubin levels later decreased,
probably as a consequence of enzyme induction, while atazanavir plasma concentrations remained
elevated.
Conclusion: This article describes an occurrence of hyperbilirubinemia in a man infected with HIV
and supports the importance of therapeutic drug monitoring in investigations of hyperbilirubinemia
among patients receiving antiretroviral agents. That the patient tolerated exceptionally high
atazanavir levels further strengthens the tolerability profile of this drug.
Introduction
The occurrence of hyperbilirubinemia has been reported
relatively frequently in clinical trials of the antiretroviral
agent atazanavir (ATV). However, hyperbilirubinemia is
generally reversible on discontinuation of treatment [1].
Hyperbilirubinemia induced by ATV resembles Gilbert's
syndrome [2]. Its symptoms include scleral icterus or
jaundice. ATV metabolism involves the enzyme uridine
diphosphate glucuronosyltransferase (UGT) 1A1, the
activity of which is inhibited by ATV at clinically relevant
plasma concentrations [1]. This may lead to a rise in
unconjugated hyperbilirubinemia. A significant correla-
tion between serum bilirubin concentration and ATV
plasma trough concentration (Ctrough) has been reported
by Ray and colleagues in a study of patients receiving
either ATV or ritonavir-boosted ATV (ATV/r) [3].
In patients receiving antiretroviral therapy, therapeutic
drug monitoring (TDM) may be a useful tool for: (i)
assessing the interindividual variability in plasma drug
concentrations, (ii) investigating the relationship between
drug concentrations and either the anti-HIV effect or drug-
related toxicities, (iii) documenting the occurrence of pos-
sible drug-drug interactions, and (iv) optimizing therapy
in individual patients [4]. We used TDM to investigate the
occurrence of hyperbilirubinemia in an HIV-infected 49-
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cerebral stroke. The patient had received several highly
active antiretroviral therapy (HAART) regimens over a
number of years, including ATV-containing regimens.
Case presentation
We present the case of a 49-year-old Hispanic man with
HIV. The patient was diagnosed HIV positive in 1984, the
infection most likely resulting from homosexual contact.
He was also hepatitis A and hepatitis B positive, was hep-
atitis C negative and had negative syphilis serology. His
total and fractionated bilirubin levels were normal and
there was no history of Gilbert's disease in his medical
record. In 2001, he suffered an episode of bacterial pneu-
monia and in 2002 he reached his CD4 count nadir, with
24 cells/mm3 and an HIV-RNA plasma viral load (HIV-
RNA pVL) of more than 600,000 copies/ml.
In 2003, he was diagnosed and treated for an oral Kaposi's
sarcoma. As a flight attendant, he had a frenetic lifestyle
and was treated for HIV infection in different countries. As
a result, his medication history included several HAART
combinations: (1) tenofovir disoproxil + didanosine +
efavirenz (TDF + ddI + EFV); (2) tenofovir disoproxil +
zidovudine + lopinavir/ritonavir (TDF + AZT + LPV/r); (3)
stavudine + didanosine + lopinavir/ritonavir (d4T+ ddI +
LPV/r); (4) stavudine + didanosine + efavirenz (d4T+ ddI
+ EFV); and (5) didanosine 250 mg once daily + tenofovir
disoproxil + efavirenz (ddI 250 + TDF + EFV). The reasons
for switching from one regimen to another between 2002
and January 2005 included virological failure, diarrhea
and the development of lipodystrophy.
When we first evaluated the patient in January 2005, his
CD4 level was 208 cells/mm3 and his viral load was
approximately 8000 copies/ml. Genotype testing showed
a 190Q mutation related to EFV and a 65R mutation
related to TDF. In the protease domain, only a 63P poly-
morphism was evident.
A new treatment regimen was started of ddI (400 mg once
daily), d4T (40 mg twice daily), and ritonavir-boosted
saquinavir (SQV/r), 1000 mg/100 mg twice daily. In Sep-
tember 2005, his HIV-RNA pVL was undetectable and
CD4 cell count had risen to 232 cells/mm3. At this time,
his total bilirubin concentration was 1.40 mg/dl (uncon-
jugated bilirubin 1 mg/dl; conjugated bilirubin 0.40 mg/
dl). A few weeks later, the patient returned to his home
country in South America and was examined again in
March 2006, during which his viro-immunological con-
trol was close to that obtained in Italy, six months previ-
ously.
In May 2006, he returned to our center complaining of
colicky abdominal pain and diarrhea with up to eight dis-
charges of loose stools per day. Scleral icterus was noted
on physical examination. After excluding drug toxicities,
viral hepatitis and alcohol abuse, it became evident that
he had been switched from SQV/r to ATV/r while in his
native country. Laboratory data showed grade 3 hyperbi-
lirubinemia (total bilirubin 5.4 mg/dl; unconjugated
bilirubin 5.1 mg/dl; conjugated bilirubin 0.3 mg/dl)
while his HIV-RNA pVL and CD4 count remained basi-
cally unchanged. His trough ATV plasma concentration
was measured by high performance liquid chromatogra-
phy (HPLC) and found to be 5.2 μg/ml, around ten times
the therapeutic level of 0.15-0.85 μg/ml [5]. The accuracy
of drug intake and blood sampling were checked and con-
firmed as correct.
The patient sought medical care in Milan due to the acute
onset of vomiting and diarrhea in May 2006, one week
after being examined in our institution. A serum total
bilirubin concentration of 7.6 mg/dl (unconjugated
bilirubin 7 mg/dl; conjugated bilirubin 0.6 mg/dl) was
noted but transaminase levels were within the normal
range, as were gamma-GT and alkaline phosphatase. He
was discharged from the emergency room with his gas-
trointestinal symptoms alleviated. In June 2006, the
patient returned to our clinic still showing mild scleral
icterus but was otherwise asymptomatic. At this stage he
presented a note from his medical practitioner from South
America that stated he had been taking 300 mg of ATV
boosted by 200 mg of ritonavir (RTV). Hence, an incorrect
RTV dosage had been taken since May 2006. A further
HPLC test in June 2006 confirmed a high level of ATV
Ctrough (5.4 μg/ml) (Figure 1). Interestingly, the total
bilirubin concentration had spontaneously decreased to
around 3 mg/dl. The RTV boosting dosage was reduced to
100 mg, resulting in a decrease of scleral icterus and a total
bilirubin concentration of 4.3 mg/ml (unconjugated
bilirubin 3.9 mg/dl; conjugated bilirubin 0.4 mg/dl). His
ATV Ctrough levels also fell, but were still above the thera-
peutic range. The patient had subsequent monthly assess-
ments. In July 2006, he presented with mild scleral
icterus, a CD4 cell count > 300 cells/mm3, and an unde-
tectable viral load. However, his total bilirubin and ATV
Ctrough were unchanged.
In August 2006, the patient's jaundice disappeared, his
serum total bilirubin concentration was markedly
reduced, and his CD4 cell count was unchanged, though
levels of HIV-RNA pVL had increased to approximately
200 copies/ml. His ATV Ctrough level was below detection
limit (0.1 μg/ml), despite his adherence to the therapy.
Thus, both the total bilirubin and the ATV Ctrough
decreased after reduction of the RTV boosting dosage. At
his last clinic visit in August 2006, the patient's total
bilirubin concentration was normal, but the ATV CtroughPage 2 of 4
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return to our clinic and was therefore lost to follow-up.
Discussion
This case report highlights several points of interest. The
inappropriate doubling of RTV boosting resulted in a high
ATV trough and an initial rise in the bilirubin plasma
level. Bilirubin levels later decreased, probably as a conse-
quence of enzyme induction, while ATV plasma concen-
trations remained elevated. An "adaptation" in bilirubin
levels during ATV-based therapy has been reported indi-
rectly at the 96-week follow-up in the BMS-045 study
(120 patients treated with ATV/r), where the incidence of
grade 3-4 bilirubin elevation was almost five times higher
in the first year of treatment than in the second year (24
versus five cases, respectively) [6]. It is also noteworthy
that the patient described here tolerated the high ATV con-
centrations, and his liver function remained within the
normal range throughout the entire period of RTV over-
dosing. This result provides additional support to the tol-
erability profile of this drug.
Conclusion
This article describes an occurrence of hyperbilirubinemia
in a man infected with HIV and supports the importance
of therapeutic drug monitoring in investigation of hyper-
bilirubinemia in people receiving antiretroviral agents.
That this patient tolerated exceptionally high ATV levels
further strengthens the tolerability profile of this drug.
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